Search
forLearn
5 / 801 resultslearn KX-826
learn Actsyl®
learn RH410
learn TDM-105795
Research
5 / 1000+ resultsresearch Abstracts Pt.21
research All ABSTRACT
research 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1
research Introduction
research 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
Community Join
5 / 1000+ resultscommunity Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
community Amplifica AMP-303 study results are expected late this summer
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
community Proof DHT is not the main cause of hair loss. TRPS1 Gene and Protein might be. PP405 won’t work. AMP-303 might!
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
community DHT Isn’t the Only Factor in Hair Loss and That Might Be the Key to a Real Cure
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
community SCUBE3 IS A GO! Clinical trials planned for later this year
SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.